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Chromium (Cr) is a widespread environmental contaminant and a known human carcinogen. We
have used shuttle vector systems in yeast, mammalian cells, and transgenic mice to characterize
the mutational specificity and premutational DNA damage induced by Cr(VI) and its reduction
intermediates in order to elucidate the mechanism by which Cr induces mutations. In the yeast
system, treatment of vector-containing cells with Cr(VI) results in a dose-dependent increase in
mutations in the SUP4-o target gene of the vector; mutagenesis is enhanced in an apn-1 yeast
mutant, deficient in the capacity to repair oxidative-type DNA damage. In vector-containing
mammalian cells, treatment with Cr(V1) also results in a dose-dependent increase in mutations in
the vector target gene supF The Cr-induced mutations in supFoccurred mostly at G:C base pairs
and were widely distributed across the gene, a pattern similar to those observed with ionizing
radiation or hydrogen peroxide. These results support the hypothesis that Cr(IVI-induced oxidative-
type DNA damage is responsible for Cr mutagenesis in the cell. Recently these studies were
extended into the Big Blue transgenic mouse system in which Cr-induced mutagenesis was
observed in the lung, the target organ for Cr carcinogenesis in humans. Analysis of the spectrum
of these mutations will test whether Cr mutagenesis occurs by similar mechanisms in the intact
animal as in cell culture systems and yeast. Environ Health Perspect 106(Suppl 4):1027-1032
(1998). http://ehpnetl.niehs.nih.gov/docs/1998/Suppl-4/1027-1032cheng/abstract.html
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Introduction
Chromium (Cr) is an essential nutrient and
a human carcinogen (1,2). Occupational
exposure to hexavalent chromium [Cr(VI)]
compounds through inhalation is associ-
ated with an increased incidence of
bronchogenic carcinoma (2,3). In occupa-
tionally exposed workers, lung tissue levels
of 100 ig/g wet weight have been reported
(4). Chromium continues to be in wide-
spread use in industry in paints, metal
plating, and as a corrosion inhibitor. It has
been identified as a primary contaminant
atapproximately one-third oftheSuperfund
Hazardous Wastesites (5). Since Cr is an
element, it cannot be removed by bio-
degradation or incineration methods, and
furthermore it may be mobilized into
groundwater sources (6). The risk to
human health from ingestion is unknown,
although a drinking water standard of0.05
mg!l has been established (7).
In the environment, Cr exists primarily
in the trivalent [Cr(III)] and hexavalent
forms; interconversion of the two forms
can occur under certain conditions (8).
Generally, Cr(VI) and not Cr(III)
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compounds have been found to be muta-
genic and carcinogenic in a variety oftest
systems (2,9). This appears to be due to
the selective penetration ofcells by chro-
mate (CrO42-) anions (9,10). Once in the
cell, Cr(VI) is subject to reduction by a
wide variety ofcellular reductants (11-13).
Glutathione (GSH) is thought to be one of
the most important intracellular reducing
agents for Cr(VI); GSH is present intracel-
lularly at mM levels and alterations in
intracellular concentrations has been
shown to affect Cr(VI)-induced toxicity
(14,15). GSH appears to have a dual role:
reactive intermediates are generated during
reduction of Cr by GSH (13,16) and
GSH serves as a radical scavenger to
protect cells agains Cr-induced oxidative
damage (17).
Cr induces both oxidative-type DNA
damage (e.g., DNA strand breaks and oxi-
dized bases) and cross-links (ternary com-
plexes ofGSH or amino acids with Cr and
DNA) (15,18-20). Cr(VI) has been shown
to be mutagenic in a variety of bacterial
and mammalian assay systems (21-23),
but the nature ofthe premutagenic DNA
damage responsible for mutation induction
has not been clearly defined. Furthermore,
the link between the mutagenic and car-
cinogenic activities of Cr compounds has
not been established.
We have undertaken a systematic
analysis of Cr mutagenesis to clarify the
role ofGSH in Cr activation and to better
define the Cr-induced DNA damage
responsible for the mutagenic activity of
Cr compounds. We have used shuttle vec-
tors in yeast (24) and mammalian systems
(25,26) and the Big Blue transgenic
mouse system (27) to investigate the
mechanism ofCr mutagenesis and to char-
acterize Cr-induced mutations. The ulti-
mate goal of this research is to elucidate
the mechanism of Cr carcinogenesis,
thereby clarifying the risk to human health
from Cr exposure.
Materials and Methods
Chemicals
Potassium dichromate (K2Cr207, 99%),
glutathione (98-100%), L-buthionine sul-
foximide (BSO), L-glutamate, L-cysteine,
and glycine were all purchased from
Sigma Chemical Company (St. Louis,
MO). 3,5-Diaminbenzoic acid (98%) was
purchased from Aldrich Chemical
Company (Milwaukee, WI).
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Yeast SUP4-0Syste
The yeast SUP4-o mutagenesis assay
system was developed by Pierce and col-
leagues (28). The plasmid YCpMP2 (28),
which carries the SUP4-o mutagenesis
target, was introduced into Saccharomyces
cerevisiae strains MKP-o [MATa,can1-
100,ade2-1,Iys2-1,ura3-52,Ieu2-3,112,his3-
D200,trpI-D901 (28)], KAM1 [radi;
defective in nucleotide excision repair
(29)], and DRY373 [apnl; defective in
oxidative DNAdamage repair (30)]. These
strains were then cultured in Uracil-defi-
cient medium and treated during exponen-
tial growth with Cr. Mutations in the
SUP4-o gene were detected on the basis
loss ofsuppression ofthree ochre markers;
mutant colonies were pink or red on cava-
nine-containing plates and failed to grow
in the absence oflysine. Mutant plasmids
were transferred to Escherichia coli strain
MBM7070 (31) for preparation of DNA
forsequencing.
mmalian SupFSystem
The pZ189 shuttle vector (31) carries the
bacterial supFgene as the mutational tar-
get, pBR322 sequences for replication and
selection in bacteria, and SV40 virus
sequences for replication in primate cells.
The E. coli tester strain MBM7070 (31)
carries the lacZ(Am)CA7020, which can
be suppressed by the supFtRNA suppres-
sor. When MBM7070 carries pZ189, it
forms blue colonies in the presence ofiso-
propyl-fP-D-thiogalactoside (IPTG) and 5-
bromo-4-chloro-3-indoyl- -D-galactoside
(X-gal); bacteria with supFmutant plas-
mids form white or light blue colonies.
Almost any mutational change in the supF
gene causes loss ofsuppressor function.
For mutagenesis testing, the vector was
transfected into African green monkey kid-
ney CV-1 cells grown in monolayer
(24,25). For in vitro treatment ofthe vec-
tor, DNA was first washed in Tris-EDTA
buffer (10 mM Tris, 1 mM EDTA, pH
7.6) and then treated with potassium
dichromate in the presence of a 5-fold
excess ofGSH in 0.1 M phosphate buffer,
pH 7.0, for 90 min at 37°C; DNA was
washed with 100 mM EDTA before trans-
fection. The EDTA treatment removes
bound Cr from the DNA. Vector DNA
was isolated 48 hr after transfection. For
treatment ofthe transfected cells, potassium
dichromate was added to the growth
medium for 12 hr, starting 6 hr after trans-
fection; vector DNAwas harvested from the
cells 72 hr after transfection. In all cases,
vector DNAharvested from transfected cells
was treated with DpnI (to degrade input
DNA) and transformed into E. coli
MBM7070 byelectroporation.
BigBlueTransgenicMouseSystnm
The C57BL/6 Big Blue transgenic mouse
carries the bacterial lad gene in a bacterio-
phage X-based vector integrated into the
mouse chromosome (32). For chromium
treatment, mice (4- to 6-week- old females)
were anesthetized, and a small surgical cut
was made in the ventral neck to expose
the trachea; a chromium solution was
injected with a 30.5-gauge needle through
the wall of the trachea into the lungs.
High molecular weight lung DNA was
isolated as described by Stratagene (33)
and the X-based vector DNA was recov-
ered by X packaging using the Stratagene
Transpack (Stratagene, La Jolla, CA).
Vector lacImutants were identified as
blue plaques on agar plates with SCS-8 E.
coli in the presence ofX-gal; wild-type
vector produced colorless plaques. Mutant
sequence analysis was carried out as
described byErfle et al. (34).
Results
To investigate Cr mutagenesis, we used
three mutagenesis assay systems. Each sys-
tem allowed the examination ofa particular
aspect of Cr mutagenesis. In the yeast
SUP4-o system (28), we took advantage of
the availability ofparticular DNA repair-
deficient strains to aid in the identification
ofthe types ofpremutagenic DNA damage
responsible for Cr mutagenesis. In the
mammalian cell pZ189 system (31), we
compared the mutation spectrum that
resulted from treatment ofthe plasmid in
vitro under controlled conditions with that
observed when the DNA was damaged
intracellularly. In the Big Blue transgenic
mouse system (32), we examined the muta-
genic potential ofCr in the lung, the target
organ for Cr carcinogenesis in humans. By
comparing results from all three systems,
we have determined mutational mecha-
nisms that appear to be common to all sys-
tems and that likely reflect the mechanisms
that contribute to human disease.
Yeast SUP4-oSystem
In theyeast system (28), the mutational tar-
get is the yeast SUP4-o suppressor tRNA
gene (25) carried on the single-copy
YCpMP2 plasmid. To characterize premu-
tagenic DNA damage in this system, we
introduced this plasmid into two repair-
deficient yeast strains. These were the
DRY373 strain, which carries the apnl
mutation and lacks apurinic endonucleasel
3'-diesterase activity (30), and the KAM-1
strain, which carries the radl mutation and
is deficient in the incision step ofnudeotide
excision repair (NER) (29). Thus, the
DRY373 strain is sensitive to agents that
cause oxidative DNA damage (e.g., hydro-
gen peroxide) and the KAM-1 strain is sen-
sitive to agents that cause bulky DNA
adducts (e.g., UV radiation). We used these
strains to determine the sensitivity to Cr
toxicityand Crmutagenicity.
For toxicity measurements, these strains
were treated with Cr compounds during
exponential growth, and survival was mea-
sured by a colony assay. For the mutagene-
sis studies, the plasmid-containing yeasts
were treated with Cr and then screened for
mutants. SUP4-o mutant plasmids were
further analyzed by DNA sequencing. To
investigate the role ofGSH in Cr toxicity
and mutagenesis, we used BSO to lower
the intracellular level ofGSH (35) and the
precursor amino acids (L-glutamate, L-cys-
teine, and glycine) to raise the intracellular
level ofGSH (36).
We found that Cr toxicity was the
greatest in the apnl DRY strain and under
conditions oflowered GSH (Table 1). Cr
mutagenesis was the highest in the DRY
strain (Figure 1) and was increased in all
strains when GSH levels were raised by
treatment ofcells with precursor amino
acids (26). These results suggest that Cr
causes premutagenic DNA damage that is
normally repaired by the product of the
APNJ gene, but not by NER. Further-
more, GSH appears to play a role in
protecting cells against Cr toxicity; but
at the same time, GSH appears to enhance
Cr mutagenesis.
In the DRYstrain, Cr induced base sub-
stitution mutations, deletions, and inser-
tions (Table 2). Base substitution mutations
likely arise from DNA base damage. About
Table 1. Survivala of yeast strains after a 3-hr expo-
sure to 0.5mM Cr(VI).
No
Yeast strains pretreatment +aab +BSOC
MKP-o 0.9 0.9 0.2
DRY(apnl) 0.7 0.7 0.01
KAM(radl) 0.9 0.9 0.2
Survival is the yeast cell density (measured by colony
formation) in log phase cultures treated with Crfor 3 hr
compared to comparable cultures without Cr treat-
ment. "Cells pretreated with 20 mM L-glutamate,1-cys-
teine, and glycine for 1 hr; GSH rose to 580% of
control; control value was 1.2 + 0.1 pmol GSH/mg cell
DNA. cCells pretreated with 1 mM BSO for 8 hr; GSH
reduced to 28% ofcontrol.
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Mammalian cells/supF
Figure 1. Mutation induction by Cr in yeast. Three
yeast strains carrying the SUP4-oplasmid were treated
with Cr(VI) for 3 hr, then the yeast were plated on indi-
cator plates to identify SUP4-o mutants. MKP-o is the
parental strain, DRY373 is mutant in the apnl gene,
and KAM-1 is mutant in the radl gene; the SUP4-o
mutant frequencies in untreated cells were 3x10-6,
1 x1D-5, and 1 x105, respectively. Cell survival at 1.5
and 3 mM Cr(VI) was 20 to 30% and 15 to 20%,
respectively, forall three yeast strains.
Table 2. Types of mutations induced in Sup4-o by
Cr(VI) treatment of DRY373p.
Number of
Types of mutation mutations detected (%)
Transitions
GC -AT 1 (2.9)
AT GC 4a(11.4)
Transversions
AT TA 0
AT-CG 5(14.3)
GC -TA 3(8.6)
GC -CG 5(14.3)
Single base insertion 0
Deletions 5(14.3)
TYelement insertion 12(34.3)
Total 34(100)
&Double mutant.
one-third ofthe mutations analyzed were
insertions ofthe yeast Ty transposable ele-
ment into one of two sites within the
SUP4-o gene. In previous studies, mobiliza-
tion of the Ty element was found to be
induced primarily by agents that cause
DNA strand breaks (37). These results sug-
gest that DNA strand breaks are another
important type ofCr-induced premutagenic
DNAdamage.
Mammalian pZ189 Sysm
In the mammalian system, the mutational
target was the bacterial supFgene carried by
an SV40-based shuttle vector plasmid,
pZ189 (31) (Figure 2). In this system, the
plasmid DNA was treated with Cr and GSH
under controlled in vitro conditions and
then introduced into the cells for replication
and mutation fixation (24); or the untreated
plasmid was introduced into the cells, and
the cells were treated with Cr (25). Under
the latter conditions, the Cr will be acti-
vated by normal cellular constituents and
gcGSW'.
In vAdam.a..s,ge .
Figure 2. The mammalian/supFsystem. The pZ189 vectorcarries the bacterial supFgene as the mutational target.
(A) The plasmid DNA is treated with Cr in vitroand then transfected into the mammalian cells where it replicates
in the nucleus. Replicated plasmid is recovered and mutants are identified by the failure to suppress an amber
mutation in the bacterial /acZgene. (B) Cells are transfected with undamaged plasmid and then treated with Cr.
Replicated plasmid is recovered and tested for mutations as in section A.
interact with the chromatized replicating
plasmid in the cell nucleus. IfCr-induced
mutations that were generated after in vitro
treatment ofthe plasmid are similar to those
generated when plasmid-containing cells are
treated with Cr, this would suggest that sim-
ilarmechanisms are involved.
When the pZ189 plasmid was treated in
vitro with Cr(VI) in the presence ofGSH
(1:5 molar ratio) there was a Cr dose-depen-
dent increase in single-strand and double-
strand breaks (assayed on agarose gels) and a
concomitant loss in biologic activity (assayed
as transformation efficiency in E. coli) (24).
In contrast, there was no measurable effect
when the DNA was treated with Cr(III) in
the presence ofGSH, or with either Cr(VI)
or Cr(III) in the absence of GSH.
Replication ofthis vector DNA in CV-1
monkey cells led to a Cr dose-dependent
increase in supFmutants with Cr(VI) plus
GSH-treated DNA, but not Cr(III)-treated
DNA (24) (Table 3). These results demon-
strate that reactive intermediates which cause
premutational DNA damage are generated
in thereduction ofCr(VI) byGSH.
We next asked whether Cr(VI) was
mutagenic in the supFsystem when vector-
containing cells were treated with Cr(VI).
Here again, mutagenesis increased in a dose-
dependent mannerwith Cr(VI) [(25); Table
4). To determine whether premutational
Table 3. Frequency of supFmutants generated in CV-1
cellstransfected with Cr/GSH-treated pZl89.
Mutation
Plasmid Mutants/total frequency
Untreated 16/63198 0.03
Cr(VI), pM
1 51/49581 0.10
5 76/21864 0.35
10 97/9274 1.05
20 47/12046 1.22
Cr(lIl), pM
1 9/11000 0.08
20 14/13940 0.10
&Treatments were conducted in the presence of a
5-fold excess of GSH in phophate buffer, pH 7.0, at
37°C for 90 min; then DNA was washed with 100 mM
EDTA and then with 10 mM Tris/1 mM EDTA before
transfection.
Table 4. Frequency of supF mutants generated in
vector-containing CV-1 cells aftertreatmentwith Cr.
Cell treatmenta Mutantfrequency
Untreated 0.05 ± 0.02b
Cr(VI), pM
10 0.15±0.03
20 0.25 ±0.08
40 1.6 ±0.03
'Treatments were for 12 hr after transfection; plasmid
was harvested after an additional 72 hr. bValues are
the mean of six separate transfections ± standard
error.
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Table 5. Characteristics of supFmutants generated after in vitro or in vivoCrtreatment.
Cr, in vitro %a Cr, in vivo, %b H202, in vitro, %C UVC, in vitro, %d
Deletions 43 39 47 3
Base substitutions
Multiples 9 18 6 27
GC changes 86 87 86 79
GC--AT 42 32 44 61
GC-TA 35 25 23 13
GC-oCG 9 30 19 5
&From Liu and Dixon (24). bFrom Liu and Dixon (25). cFrom Moraes et al. (38). dFrom Hauser etal. (39).
Big Bluemouse/lac/
DNA damage induced inside the cell by Cr
was similar to that generated in vitro by Cr
in the presence ofGSH, we compared the
spectra of supFmutations induced under
the two conditions (25). We argued that
similar spectra would suggest similar muta-
tional mechanisms and different spectra
would argue for different mechanisms.
Mutant plasmids were characterized by
agarose gel electrophoresis to screen for
large insertions and deletions and by DNA
sequencing to identify smaller changes. A
total of 141 mutants were analyzed from
the in vitro Cr treatment (24) and 89
mutants were analyzed from the treatment
ofvector-containing cells (Table 4) (25).
Comparison of the mutants induced
following in vitro treatment ofthe vector
with Cr plus GSH and the mutants
induced when vector-containing cells were
treated with Cr in vivorevealed many simi-
laritites (Table 5) (24,25). A large percent-
age ofthe mutations were deletions, similar
to that observed with H202-treated plas-
mid (38) and unlike UWC-treated plasmid
(39). Most ofthe mutations occurred at
GC base pairs with a large fraction of
GC -- TA as well as GC ->AT base substi-
tutions; this distribution is also similar to
H202-treated plasmid and not UVC-
treated plasmid. The fraction ofmultiple
mutations appeared to be somewhat higher
when the cells were treated with Cr versus
treatment ofplasmid.
To compare the mutation spectra with
respect to the distribution of mutations
within the supFgene, we carried out an
analysis (25) using the method described
byAdams and Skopek (40). A comparason
of the spectra of mutations within the
tRNA coding sequence generated by
Cr(VI) in vivo and in vitro revealed no sig-
nificant difference (p>0.05). A similar
comparison of the two H202 spectra
revealed no significant difference. In con-
trast, comparison ofthe Cr(VI) and H202
in vivo spectra revealed significant differ-
ences (p<0.001); in particular, several
hot spots were observed in the Cr(VI)
spectrum that were not observed in the
H202spectrum. Thus, despite overall simi-
larities-i.e., mutations occurred primarily
at GC base pairs and were widely distrib-
uted along the target sequence-differ-
ences at mutational hot spots were
observed in vivo. These in vivo differences
may reflect differences in the way Cr(VI)-
and H202-generated reactive intermediates
interact with DNA in the context ofother
cellular proteins.
BigBlueTransgenicMouseSystem
To relate mutagenesis data from cell culture
to Cr mutagenesis in the target organ rele-
vant to carcinogenesis, we next used the Big
Blue transgenic mouse system (Figure 3). In
this system, the lad mutagenesis target is
carried in a bacteriophage X-based vector
tandemly integrated into the mouse chro-
mosome. These mice were treated with
Cr(VI) by intratracheal instillation into the
lung, and 1 to 4 weeks later the mice were
sacrificed, the lungs were removed, and
high molecular weight DNA was isolated.
The vector DNA was recovered by X pack-
aging and lad mutants were identified by
plaque color on indicatorplates.
We observed a time-dependent (1-4
weeks; data not shown) and Cr(VI) dose-
dependent (1.7-6.8 mg/kg) increase in the
frequency of lad mutants in vector DNA
from the lungs oftreated mice (Table 6).
This is the first demonstration ofCr(VI)-
induced mutations in an experimental ani-
mal. Further studywill be required to relate
this mutagenesis to the carcinogenic activity
of Cr compounds. Nevertheless, these
results suggest that Cr has the mutagenic
potential to be a genotoxic carcinogen.
Plaques
Figure 3. The Big Blue mouse system. The transgenic
mice carrying the lacltarget gene in an integrated
X-basedvector, aretreatedwith Crby instillation intothe
lung. Later, animals are sacrificed, the lungs are
removed, and lung DNA is isolated. Target gene
sequences are recovered by x packaging and lacl
mutants are identified byplaquecoloron indicatorplates.
Discussion
The carcinogenic potential of certain
chromium compounds has been recognized
for several decades. This has led to the
implementation ofrestrictions on human
exposures and concern about thehigh levels
ofchromium contamination at many waste
sites. Despite these concerns, chromium
compounds are still used in large quantities
in industry and the potential for human
exposure remains. Although chromium
compounds have been shown to be muta-
genic in a variety oftest systems, the mech-
anism of mutagenesis has not been well
understood. Furthermore, it is not clear
what level ofdanger is posed by environ-
mental sources ofchromium. The work
described here focuses on an analysis of
Table6. Laclmutantfrequency in mouse lung DNA4weeks after Cr(VI) instillation.
Treatment Mutants/PFU Mean MF± SDa
Saline 13/492,080 2.6 ± 0.5x 10
1.7 mg/kg Cr(VI) 21/511,310 4.1 ±0.8x 105
3.4 mg/kg Cr(VI) 31/400,690 7.7 ± 2.2x 105
6.8mg/kg Cr(VI) 45/361,380 12.5 ± 1.7 x 1 -5
Abbreviations: PFU, plaque-forming unit; MF mutantfrequency. aFour micewere analyzed pergroup.
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mechanisms by which chromium induces
DNA damage and causes mutations. The
long-range goal ofthis work is to enhance
our understanding of the links between
chromium exposure, DNA damage, muta-
genesis, and carcinogenesis to provide a
rationale for assessing the risks associated
with human environmental exposures.
By using both yeast and mammalian
cells we have demonstrated that Cr(VI)-
induced DNA damage leads to deletions,
DNA rearrangements, and base substitution
mutations. The pattern ofbase substitution
mutations resembles that induced byagents,
such as hydrogen peroxide and ionizing
radiation, that cause oxidative DNA dam-
age. In particular, mutations were observed
primarily at GC base pairs and were distrib-
uted widely within the target gene. This is
the first comparison ofthe mutational speci-
ficity ofchromium to other oxidative agents
in a system that allows the detection ofa
broad spectrum ofmutational events. We
did observe differences among these spectra
at a few mutational hot spot sites (25). The
mutational specificity of chromium in
human cells was also examined using the
denaturing gradient gel electrophoresis
method developed by Chen and colleagues
(23). Ofthe four sites at which chromium-
induced base substitutions were detected in
that system, three were GC base pairs; these
hot spots differed from those detected in
thatsystem after H202 treatment (23). This
difference in mutational hot spots is consis-
tent with our observations in the shuttle
vector systems. Yang et al. (22) also exam-
ined the mutational specificity ofchromium
in the hprtgene ofChinese hamster ovary-
KI cells. They reported dominant base
changes at AT sites with mainly T--A and
T- G transversions. These data may indi-
cate that the base substitution specificity of
chromium mutagensis is species specific.
Our studies with transgenic mice
demonstrate that Cr(VI) is mutagenic in
the target organ (lung) relevant to human
chromium carcinogenesis. Despite the rela-
tive insensitivity of this system to muta-
genesis, we detected a large increase in
mutagenesis after exposure to chromium.
While the levels ofchromium used in this
study are well above those associated with
human exposure, these studies confirm that
chromium has the potential to act as a
genotoxic carcinogen in the intact organ-
ism. Further analysis of the spectrum of
mutations in this system should allow a
better understanding of the mutational
mechanisms operative in the intact organ-
ism. In addition, this system can be uti-
lized to determine the potential for
chromium genotoxicity in other organs
and by other routes of exposure. In
particular, it will be of interest to deter-
mine whether exposures that are more rele-
vant to environmental contamination (e.g.,
drinking water) also cause mutagensis in
this system.
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